A study by Vall d’Hebron shows that rheumatic patients treated with immunomodulatory therapies do not have an increased risk of COVID-19 infection
July 26, 2021 11:03 amCategorised in:
This post was written by Miguel
Categorised in:
This post was written by Miguel